Zombie Cells Are Destroying Your Body From Within. Scientists Are Finally Learning How to Kill Them.

Every day, millions of your cells stop dividing but refuse to die. They linger in your tissues, leaking a toxic cocktail of inflammatory molecules that damages neighboring cells, accelerates aging, and fuels diseases from Alzheimer’s to diabetes to heart failure. Scientists call them senescent cells. The popular press calls them zombie cells. And for the first time in medical history, researchers are closing in on practical ways to eliminate them.

Presented By Our Partners

The science of cellular senescence has reached an inflection point in 2025 and 2026. A pilot clinical trial published in The Lancet’s eBioMedicine tested the first senolytic drug combination in patients at risk of Alzheimer’s disease. Unity Biotechnology’s Phase 2b trial of a senolytic eye therapy delivered meaningful vision improvements in patients with diabetic macular edema. And a team at Cold Spring Harbor Laboratory demonstrated that engineered CAR-T immune cells can seek and destroy senescent cells with a precision that small molecules cannot match, offering protection against metabolic dysfunction that persists for months after a single treatment.

Meanwhile, researchers at the Mayo Clinic and other institutions have identified blood-based biomarkers that can measure the burden of senescent cells in living people, opening the door to clinical trials that can finally quantify whether clearing zombie cells translates into longer, healthier lives.

This is no longer speculative biology. This is medicine on the cusp of a paradigm shift.

What Are Senescent Cells and Why Do They Matter?

Cellular senescence is a state of permanent growth arrest that cells enter in response to damage. When a cell’s DNA is severely harmed by radiation, toxins, or the accumulated errors of replication, it faces a choice: die through programmed cell death (apoptosis) or lock itself into a state where it can no longer divide. Senescence is the body’s way of preventing damaged cells from becoming cancerous. In youth, this is a protective mechanism. The immune system routinely identifies and clears these frozen cells, keeping their numbers low.

The problem begins in middle age. As the immune system weakens and the rate of cellular damage increases, senescent cells accumulate faster than the body can remove them. By age 60, the burden of senescent cells in tissues like the skin, liver, lungs, and kidneys can be several times higher than at age 30.

These lingering cells are far from inert. They secrete a complex mixture of inflammatory cytokines, growth factors, and tissue-degrading enzymes collectively known as the senescence-associated secretory phenotype, or SASP. Interleukin-6, interleukin-8, matrix metalloproteinases, and transforming growth factor-beta are among the most damaging components. This secretory cocktail spreads inflammation to surrounding healthy cells, converting some of them into senescent cells in a chain reaction that researchers call paracrine senescence.

A landmark review published in the journal Physiology by Yang Zhang and Anthony Rosenzweig at the University of Michigan’s Frankel Institute for Heart and Brain Health, along with Houzao Chen at Peking Union Medical College, documented how senescent cells in one organ can influence distant tissues through blood-borne SASP factors, extracellular vesicles, immune cell dynamics, and neuroendocrine signals. The result is what the authors describe as asynchronous aging, where senescence in one organ like the gut accelerates deterioration in seemingly unrelated organs like the brain.

This interorgan communication explains a puzzle that has long frustrated clinicians: why aging seems to accelerate across multiple organ systems simultaneously, and why a disease in one organ so often predicts decline in another.

Dasatinib and Quercetin: The First Senolytics Reach Alzheimer’s Patients

The most advanced senolytic therapy in human testing is the combination of dasatinib, a leukemia drug that inhibits the survival pathways senescent cells depend on, and quercetin, a plant flavonoid with complementary anti-senescence properties. James Kirkland and his colleagues at the Mayo Clinic pioneered this combination, first demonstrating in 2015 that it could extend healthspan in aged mice.

A decade of preclinical work led to the first pilot clinical trial in patients at risk for Alzheimer’s disease, published in The Lancet’s eBioMedicine in early 2025. Twelve older adults with mild cognitive impairment received 100 milligrams of dasatinib and 1,250 milligrams of quercetin for two consecutive days every two weeks over a 12-week period. The trial was designed primarily to assess feasibility and safety, and on both counts, the results were encouraging.

There were no serious adverse events related to the intervention. Participants showed a mean increase of 1.0 point on the Montreal Cognitive Assessment, a widely used screening tool for cognitive decline. While this improvement did not reach statistical significance in such a small cohort, the direction of effect was consistent with the hypothesis that clearing senescent cells from the brain’s vasculature and surrounding tissue could slow or partially reverse cognitive decline.

The study is now being expanded into a larger Phase 2 trial with 30 or more participants to determine whether these preliminary signals translate into clinically meaningful cognitive preservation.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Separately, a protocol published in mid-2025 outlined a pilot trial of dasatinib plus quercetin in patients with schizophrenia and treatment-resistant depression. The rationale is that psychiatric disorders are associated with accelerated biological aging, higher burdens of senescent cells, and elevated inflammatory markers. If senolytics can reduce the biological age of the brain in these patients, it could represent an entirely new class of psychiatric treatment.

Unity Biotechnology and the Eyes: Senolytics Go Local

While dasatinib and quercetin work systemically, Unity Biotechnology has pursued a different strategy: delivering senolytics directly to diseased tissue. Their lead candidate, UBX1325, is a small-molecule Bcl-xL inhibitor designed to eliminate senescent cells in the retina. Bcl-xL is one of the key anti-apoptotic proteins that senescent cells hijack to avoid death, and blocking it selectively triggers their demise.

In the Phase 2b ASPIRE trial, 52 patients with diabetic macular edema who had poor vision despite prior anti-VEGF treatment were randomized to receive either UBX1325 or aflibercept (the current standard of care) injections every eight weeks for six months. The results, published in NEJM Evidence, showed that UBX1325-treated patients gained an average of 5.2 letters on the standard eye chart at 24 weeks and 5.5 letters at 36 weeks.

The trial narrowly missed its pre-specified non-inferiority endpoint at a 90 percent confidence interval, achieving it instead at 88 percent. But the clinical significance is hard to dismiss: patients who had already failed the best available treatment gained meaningful vision with a drug that works through an entirely different mechanism. Rather than suppressing the symptoms of vascular leakage as anti-VEGF drugs do, UBX1325 eliminates the senescent cells that drive the disease process itself.

The safety profile was notable as well. Across all Unity studies of UBX1325, there have been no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis, the serious complications that plague other retinal therapies.

CAR-T Cells: Programming the Immune System to Hunt Zombie Cells

Perhaps the most transformative development in the senolytic field is the repurposing of chimeric antigen receptor T-cell (CAR-T) therapy to target senescent cells. CAR-T therapy, which has revolutionized blood cancer treatment, works by engineering a patient’s own T cells to recognize and destroy cells bearing a specific surface marker. Researchers have now identified several markers enriched on senescent cells, most notably urokinase plasminogen activator receptor (uPAR).

In a study published in Nature Aging, Corina Amor and colleagues at Cold Spring Harbor Laboratory demonstrated that a single infusion of anti-uPAR CAR-T cells into aged mice produced remarkable and long-lasting results. The engineered immune cells sought out and eliminated senescent cells across multiple tissues, leading to improved glucose tolerance, enhanced exercise capacity, and reduced markers of metabolic dysfunction. Most strikingly, these benefits persisted for months after treatment, suggesting that the CAR-T cells established a form of immunological memory against senescence.

The implications are profound. Unlike small-molecule senolytics such as dasatinib and quercetin, which require repeated dosing and affect all cells expressing certain survival proteins, CAR-T cells can be engineered for exquisite specificity. They can distinguish senescent cells from healthy cells based on surface markers, reducing the risk of off-target effects. And because they can persist in the body and even proliferate in response to their target, a single treatment could provide years of senescent cell surveillance.

A comprehensive 2025 review published in Frontiers in Immunology noted that researchers are now exploring additional senescence-associated surface markers beyond uPAR, including NKG2D ligands and TSPAN8, to develop second-generation senolytic CAR-T therapies with even greater precision. The review also highlighted emerging strategies to address one of the key challenges: immunosenescence, the age-related decline in immune function that could limit the efficacy of CAR-T therapy in the elderly patients who need it most.

Measuring Zombie Cells in Living People: The Biomarker Breakthrough

One of the greatest obstacles to proving that senolytics work in humans has been the inability to measure senescent cell burden in living people. You cannot biopsy every organ. Until recently, researchers relied on indirect proxies like inflammatory markers in the blood, which are influenced by dozens of factors beyond senescence.

That obstacle is now falling. A study published in Aging Cell in 2025, led by researchers at the Mayo Clinic, characterized a panel of human senescent cell biomarkers suitable for clinical trials. The most validated marker is p16INK4a expression in circulating T cells, specifically the variant 5 isoform. Higher T-cell p16 expression correlates with greater tissue-level senescent cell burden and with worse outcomes across multiple age-related conditions.

A parallel study published in GeroScience tracked longitudinal changes in blood-borne geroscience biomarkers in a population-based cohort of adults over 60, measuring 47 biomarkers across four physiological domains including cellular senescence. The results showed that higher levels of senescence-associated proteins like GDF15 and interleukin-6 predicted increased risk of all-cause mortality, mobility limitation, and heart failure, even after adjusting for traditional risk factors like age, sex, and cardiovascular history.

These biomarkers serve a dual purpose. First, they allow clinical trialists to select patients with the highest senescent cell burden, the individuals most likely to benefit from senolytic therapy. Second, they provide a measurable endpoint: if a senolytic drug reduces circulating p16 or GDF15 levels and that reduction correlates with improved health outcomes, it becomes possible to demonstrate efficacy without waiting years for hard endpoints like death or dementia diagnosis.

Senescence and the Diseases of Aging: The Expanding Map

The therapeutic landscape for senolytics continues to broaden. A comprehensive review published in Ageing Research Reviews in March 2026 by Runjin Zhou and colleagues mapped the connections between cellular senescence and neurodegenerative diseases, identifying senescent microglia as a particularly promising therapeutic target. These are the brain’s resident immune cells, and when they become senescent, they shift from a protective role to one that amplifies chronic neuroinflammation, accelerating the progression of Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis.

In the kidneys, a major review published in Kidney International by LaTonya Hickson and colleagues at the Mayo Clinic documented how cellular senescence drives diabetic kidney disease, the leading cause of chronic kidney disease worldwide. The authors described an explosion of research over the past five years into senotherapeutics for this condition, including not just small-molecule senolytics but also mesenchymal stem cell therapies, hydrogel-based tissue engineering approaches, and even CRISPR gene-editing strategies designed to reduce the senescent cell burden in kidney tissue.

In the cardiovascular system, a 2026 study in Acta Physiologica demonstrated that the senolytic agent ABT-263 could rescue drug-induced vascular injury in mice, providing evidence that senescent cells play a direct causal role in certain forms of hypertension and microvascular damage.

The cancer field is also paying close attention. A review published in Mechanisms of Ageing and Development identified senescent cancer-associated fibroblasts as a major contributor to tumor progression. These cells secrete SASP factors that promote tumor cell proliferation, suppress anti-tumor immunity, and drive resistance to chemotherapy. Targeting them with senolytics or CAR-T cells could make existing cancer treatments more effective.

What This Means For You

The science of cellular senescence has moved from laboratory curiosity to clinical reality. While no senolytic drug is yet approved for general use, the evidence base is growing rapidly, and several developments are directly relevant to your health decisions today.

First, the risk factors that accelerate senescent cell accumulation are largely the same ones that accelerate aging in general: chronic inflammation from poor diet, sedentary behavior, sleep deprivation, excessive alcohol consumption, and chronic psychological stress. Reducing these exposures may slow the rate at which zombie cells accumulate in your tissues, buying time until targeted therapies become available.

Second, quercetin, one half of the most studied senolytic combination, is widely available as a dietary supplement. While the doses used in clinical trials (1,250 milligrams combined with a prescription drug) are much higher than typical supplement doses, and while quercetin alone is far less potent than the combination, there is some preclinical evidence that regular quercetin intake may provide modest senomorphic benefits by dampening the SASP without fully clearing senescent cells.

Third, exercise remains the most potent natural senolytic. Multiple studies have shown that regular physical activity reduces the accumulation of senescent cells in muscle, fat, and vascular tissue, likely through a combination of improved immune surveillance and reduced chronic inflammation.

Fourth, if you are living with a condition that may involve senescent cell accumulation, including diabetic eye disease, chronic kidney disease, osteoarthritis, or cognitive decline, ask your physician about clinical trials. The National Institutes of Health’s SenNet Consortium and ClinicalTrials.gov maintain updated registries of ongoing senolytic studies, and participation could give you access to these therapies years before they reach the market.

The zombie cells in your body have had free rein for decades. The era when medicine can finally fight back is arriving faster than most people realize.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.